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Abstract
The Toll/interleukin-1 (IL-1) receptor (TIR) family comprises two groups of transmembrane proteins, which share functional and
structural properties. The members of the IL-1 receptor (IL-1R) subfamily are characterized by three extracellular immunoglobulin (Ig)-
like domains. They form heterodimeric signaling receptor complexes consisting of receptor and accessory proteins. The members of the
Toll-like receptor (TLR) subfamily recognize alarm signals that can be derived either from pathogens or the host itself. TLRs possess
leucine-rich repeats in their extracellular part. TLRs can form dimeric receptor complexes consisting of two different TLRs or
homodimers in the case of TLR4. The TLR4 receptor complex requires supportive molecules for optimal response to its ligand
lipopolysaccharide (LPS). A hallmark of the TIR family is the cytoplasmic TIR domain that is indispensable for signal transduction. The
TIR domain serves as a scaffold for a series of protein–protein interactions which result in the activation of a unique signaling module
consisting of MyD88, interleukin-1 receptor associated kinase (IRAK) family members and Tollip, which is used exclusively by TIR
family members. Subsequently, several central signaling pathways are activated in parallel, the activation of NFnB being the most
prominent event of the inflammatory response. Recent developments indicate that in addition to the common signaling module MyD88/
IRAK/Tollip, other molecules can modulate signaling by TLRs, especially of TLR4, resulting in differential biological answers to
distinct pathogenic structures. Subtle differences in TLR signaling pathways are now becoming apparent, which reveal how the innate
immune system decides at a very early stage the direction in which the adaptive immune response will develop. The creation of
pathogen-specific mediator environments by dendritic cells defines whether a cellular or humoral response will be activated in response
to the pathogen.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In mammals, challenge by bacteria and viral pathogens
results in a rapid activation of the immune system to mount
a fast and adequate response. The activation of specialized
receptors for pathogen-associated structures on sentinel
cells is translated into the production and release of
endogenous alarm mediators. The master cytokines inter-
leukin-1h (IL-1h) and tumor necrosis factor a (TNFa), but
also IL-12 and IL-18, are rapidly released by these cells of
first line defense. They orchestrate the acute response
required to support the local phagocytes in their effort to
control the pathogens before they can spread systemically.
Interestingly, the receptors recognizing many pathogen-
associated structures, the human Toll-like receptors (TLRs),
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and the receptors for the endogenous pro-inflammatory
cytokines IL-1 and IL-18, share a cytoplasmic motif, the
Toll/IL-1 receptor (TIR) domain, which is required for
initiating intracellular signaling. The TIR family not sur-
prisingly seems to utilize very similar signaling mecha-
nisms to activate downstream effector mechanisms. While
some components of the downstream signaling machinery
like the adapter TNF receptor associated factor 6 (TRAF6)
are shared by other receptors of proinflammatory cyto-
kines, one signaling module is exclusively employed by
the TIR family. This consists of MyD88, interleukin-1
receptor associated kinase (IRAK) family members and
Tollip.
Thus, these receptors are not only grouped into one
family because of the sharing of TIR domains and utiliza-
tion of the MyD88/IRAK module but also functionally, as
they include pivotal alarm receptors of the innate immune
system. It needs to be stressed, however, that both IL-1 and
IL-18 are not just mediators of the innate immune response.
Both cytokines are centrally involved in the development,
proliferation and differentiation of T helper cells and B cells.
Thus, they represent key elements at the interface of innate
and adaptive immune responses.
The aim of this review is to critically discuss the present
concepts of signal initiation in the TIR family and highlight
apparent differences emphasizing the initial receptor-prox-
imal events rather than downstream effects.
2. The family of TIRs
Members of the family of TIRs have been described in
vertebrates, invertebrates and plants. Some family members
are important at certain developmental stages in ontogeny,
the best-characterized molecule being Drosophila Toll,
which is involved in the embryonic development and
dorsal–ventral polarity in insects.
The main functional reason to group these molecules is
that, as far as is known, all members of the TIR family are
involved in protection against viral, bacterial or protozoal
infections in adult organisms of animals or plants alike. They
are crucial mediators of host defense (reviewed in Ref. [1])
and can be dubbed alarm receptors of the host defense system.
In addition to their biological function, there is also a
clear structural reason to group these diverse molecules into
one family: they share a common intracellular motif which
is essential for the signaling of these receptors or adapters.
This motif is called the TIR motif or the TIR domain
(reviewed in Ref. [2]). With the exception of the type II
IL-1 receptor (IL-1R), which does not signal, all trans-
membrane or cytoplasmic members of the TIR family
contain this TIR domain. Signaling of this family of
receptors is similar but not identical in vertebrates and
invertebrates (reviewed in Ref. [3]).
The TIR family may be roughly grouped into three
groups defined by their structural features (Fig. 1).
Fig. 1. The human TIR family. The TIR family consists of three subfamilies, two transmembrane receptor subfamilies and the MyD88 adapter family. (Soluble
receptors are not depicted for the sake of clarity.)
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2.1. The IL-1R subfamily
The IL-1R subfamily comprises type I transmembrane
molecules and soluble forms, which are characterized by
extracellular immunoglobulin (Ig)-like domains. The proto-
types of this family are the IL-1R type I [4] and its
respective coreceptor molecule, the IL-1RAcP [5]. A few
years ago, the subfamily member formerly known as IL-
1Rrp1 [6] was identified as the a chain of the IL-18 receptor
[7]. Subsequently, the IL-18 rector h chain (IL-18RAcP)
was cloned and turned out to be a structural and functional
homologue to IL-1RAcP [8]. In both cases, the receptor
chains (type I IL-1 R, or IL-18 Ra) contain the ligand
binding site, whereas the respective coreceptors IL-1RAcP
or IL-18Rh are incapable of binding the cytokine alone.
A series of orphan receptors share the features of the
receptors for IL-1 and IL-18 (compared in Ref. [9]). They
also contain three extracellular Ig-like domains, they are
type I transmembrane molecules and possess a TIR domain
in their cytoplasmic part. One family member, single Ig-
domain containing IL-1R related (SIGIRR), possesses a
single extracellular Ig-like domain [10], whose function is
unclear. It is very likely that they are receptors or corecep-
tors for novel members of the IL-1 family [11–13]. For the
two new forms, IL-1y and IL-1q, it was very recently shown
that they function as agonist (IL-1q) and as antagonist (IL-
1y) of IL-1Rrp2, possibly constituting a novel ligand/recep-
tor pair of the IL-1R subfamily [14]. The type II IL-1R is a
transmembrane molecule with the extracellular feature of
the IL-1R family, but is lacking a cytoplasmic TIR domain
[15]. Its function seems to be of a regulatory nature. Two
mechanisms have been described for type II IL-1R which
modulate the responsiveness of cells to IL-1: One is ligand
sequestration [16], and the other one is competition for the
coreceptor [17]. The type II IL-1R thus functions as a true
decoy receptor (reviewed in Ref. [18]). The transmembrane
molecules of the IL-1R subfamily are depicted on the left
side of Fig. 1. Soluble IL-1Rs or the IL-18 binding protein
have regulatory functions by sequestering IL-1 or IL-18;
they do not initiate signal transduction.
2.2. The TLR subfamily
The TLR subfamily comprises a growing number of
molecules which share leucine-rich repeat domains (re-
viewed in Refs. [1,19,20]). These molecules are also type
I transmembrane molecules in animals, but seem to be
cytoplasmic molecules in plants [21]. The members of the
Toll-like subfamily also contain a cytoplasmic TIR domain
which is essential for signal generation (an exception may
be RP-105). The prototype of this subfamily is the Droso-
phila Toll protein. In the ontogeny of the fruit fly, this
receptor is activated by its protein-ligand Spa¨tzle, which
initiates a signaling cascade resulting in the activation of the
transcription factor Dorsal and induction of dorsal–ventral
patterning [22]. In the adult fly, Toll is involved in anti-
fungal protection [23], but the ligands activating Toll-
mediated host defense mechanisms are not known. 18
wheeler was reported to be the insect counterpart respon-
sible for anti-bacterial reactions [24]. This has been ques-
tioned recently as discussed in Ref. [25]. In insects,
presently a total of nine TLRs were described [26] which
play a role in host defense and development. Comparison of
human expressed sequence tags with the Drosophila Toll
sequence identified a human Toll homologue, which upon
overexpression activated proinflammatory signaling path-
ways [27]. In this seminal publication, it was suggested for
the first time that this molecule, later dubbed human TLR4,
was a receptor for pathogens [27].
The human TLRs have now been identified as receptors
for pathogen-associated structures (reviewed in Ref. [28]).
The prototypes of this subfamily are TLR2 and TLR4. The
discovery that TLRs are receptors for pathogen-associated
membrane patterns and that these receptors belong to the
TIR family, opened a new and permanently growing field
and revived research in innate immunity (commented in
Ref. [29]). TLRs recognize a variety of molecules derived
from pathogens such as bacterial cell wall components and
heat shock proteins (TLRs 1,2,4,6) [28–38], flagellins
(TLR5) [39,40], viral dsRNA and polyI:C (TLR3) [41],
and small anti-viral compounds (TLR7) [42], and CpG-
DNA (TLR9) [43], but also eukaryotic proteins which
appear after destruction of cells or tissues such as heat
shock proteins [44] or fibrinogen [45], signs of wounding,
often being a consequence of infection. In that sense, maybe
TLRs should be more appropriately addressed as danger
sensors, supporting the notion that the immune system
differs between non-dangerous and dangerous structures
rather than between self and non-self (reviewed in Ref.
[46]).
Discussion of the exploding number of important pub-
lications identifying novel ligands for TLR family members
would go beyond the scope and aim of this review. The
evolving overall picture suggests two basic principles. First,
TLRs recognize more than one ligand, which often do not
share any obvious structural similarity and which can be
derived from pathogens or the host. Second, TLRs form
receptor complexes that may consist of at least two different
TLRs, or in the case of the lipopolysaccharide (LPS)
receptor, of a TLR4 homodimer requiring MD-2 [47] and
CD14 (reviewed in Ref. [48]) to bind LPS. Presently, 10
coding family members have been definitely described in
humans (reviewed in Refs. [49,50]). Anecdotal rumors
claim even more TLRs. It is tempting to speculate that
different combinations of individual TLRs will define differ-
ent specificities for pathogen-associated structures.
The TLR subfamily members are differentially expressed
in tissues or immune competent cells with a certain degree
of specificity (Refs. [51–53], summarized in Ref. [19]). An
increasing number of recent reports describe regulation of
TLRs in several cell types and tissues, mainly on mRNA
level, by microbial signals and cytokines demonstrating that
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regulating of TLRs adds a further level of complexity to
innate immunity [54–57].
2.3. The mammalian molecule MyD88
The mammalian molecule MyD88 clearly does not fit the
classification of either the IL-1R subfamily or the TLR
subfamily and defines a third subfamily. Very recently, a
MyD88-like protein was identified independently by two
groups, one calling it MyD88-like adapter protein or
MyD88-adapter-like (Mal) [58], the other TIRAP for TIR
domain-containing adapter protein [59]. Neither MyD88 nor
Mal/TIRAP are receptors. They are ubiquitously expressed
cytoplasmic molecules characterized by a TIR domain.
MyD88 contains an N-terminal death domain and is an
indispensable adapter in the signaling cascade of all TIR
family members [60–64]. Mal/TIRAP is 75 amino acids
shorter in the N-terminus and thus lacks a death domain. It
was reported to interact with TLR4 [58,59].
3. TIR complexes
3.1. The IL-1R complex
The type I IL-1R binds IL-1a, IL-1h and the receptor
antagonist IL-1Ra (reviewed in Ref. [65]). The crystal
structure of the extracellular part of type I IL-1R bound to
IL-1 was determined [66,67]. The ligated type I IL-1R is
recognized by IL-1RAcP [5]. A model for the interaction of
the extracellular parts of type I IL-1R and IL-1RAcP with
IL-1h was proposed [68]. The result of this interaction is the
formation of a heterodimeric transmembrane receptor com-
plex (Fig. 2A). Both molecules are required for initiation of
signal transduction, lack of the coreceptor results in non-
responsiveness to IL-1 [69–72]. Soluble type I or soluble
type II IL-1R is involved in regulation of IL-1 responsive-
ness by sequestering IL-1. Ligand transfer for IL-1 has not
been reported.
3.2. The IL-18 receptor complex
IL-18 binds to the IL-18 receptor a chain (IL-1Rrp1) [7],
and the ligated receptor is recognized by the IL-18 h chain
(AcPL) [8], forming a heterodimeric transmembrane recep-
tor (Fig. 2B). Again both receptor chains are needed for
signal transduction.
Although the molecules of the IL-1R complex and the
IL-18 receptor complex are closely related, they cannot
substitute for each other. The receptors are specific for their
respective ligands and the coreceptors recognize only the
respective ligated receptors. Of interest is the considerable
Fig. 2. Heterodimeric receptor complexes in the TIR family. (A) The IL-1
receptor complex. The type I IL-1 receptor binds IL-1a or IL-1h and then
interacts with the IL-1RAcP to form a heterodimeric signaling receptor
complex. Receptor and coreceptor contribute an individual TIR domain
each. Soluble type I or type II IL-1 receptors and membrane-inserted type II
IL-1R regulate IL-1 responsiveness by sequestering ligand or IL-1RAcP.
(B) The IL-18 receptor complex. The a chain of the IL-18 R [formerly IL-1
receptor related protein (Rrp) 1] binds IL-18 and then interacts with the h
chain of the IL-18R, the accessory protein-like chain to form a hete-
rodimeric signaling receptor complex. Receptor and coreceptor contribute
an individual TIR domain each. Soluble IL-18 binding protein binds IL-18
and neutralizes it. (C) Heterodimeric Toll-like receptor complexes. Toll-like
receptor 2 can interact either with TLR1 or TLR6 to bind bacterial struc-
tures. It is presently unclear where the ligands bind exactly. It is assumed
that the different TLRs contribute individual TIR domains to the signaling
receptor complex. (A possible role for MD-2 in the TLR2 complex has not
been depicted for the sake of clarity.)
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difference in affinities of the receptor complexes for their
respective ligands: The affinity of the IL-1R complex for IL-
1a or IL-1h is in the range of 0.2 nM [15], whereas the
affinity of the IL-18 receptor complex for IL-18 is around 20
nM [7,8,73]. A soluble IL-18 binding protein exists which
can efficiently neutralize IL-18 [74,75].
The depicted models of functional heterodimers are
minimalistic ones. It is unclear whether the heterodimeric
receptor complexes of the TIR family form oligomers or
larger complexes, as has been described for other families of
cytokine receptors. A study employing fluorescence reso-
nance energy transfer (FRET) suggested that type I IL-1R
clusters upon stimulation of cells with IL-1 [76]. Further
characterization of different receptor complexes with bio-
physical means will help to clarify this issue.
3.3. The heterodimeric TLR complexes
The principle of generating heterodimers for signal trans-
duction through the membrane is also utilized by family
members of the TLRs. Recent publications suggest that
TLR1 and TLR6 serve as coreceptors or modulators for
TLR2 [77,78]. This fits nicely as no ligand for TLR1 alone
has been described to date; thus, it could play the coreceptor
role of IL-1RAcP or IL-18Rh chain in the IL-1R subfamily.
In addition, collaboration of TLR2 and TLR6 in the recog-
nition of soluble tuberculosis factor and Borrelia burgdor-
feri outer surface protein A lipoprotein was described [79],
which would suggest that more heterogeneous TLR com-
plexes are conceivable. Comparative reconstitution and
complementation experiments are required to clarify this
important issue. The ability to recognize so many diverse
pathogen-associated structures by a limited number of TLRs
could be potentially achieved by different combinations of
TLRs. The prototype of a heterodimeric TLR complex is
depicted in Fig. 2C, although no cross-linking studies have
been published yet to define ligand binding sites in either of
the two participating TLRs (for TLR4, see below). Besides
the participation of CD14 in TLR2 signaling upon LPS
stimulation [32,80,81], no additional extracellular or trans-
membrane molecules were reported to be required for TLR
signal transduction. However, it cannot be excluded that
ubiquitously expressed proteins participate in these receptor
complexes, which have not yet been identified. It is also
unclear whether different subsets of TIR domains are
required for signal initiation, for example, contributed by
different receptor-like TLRs and accessory-protein-like
TLRs as in the IL-1 and IL-18 receptor complexes.
3.4. The homodimeric TLR4 complex
TLR4 is somewhat different to the other family members.
Formation of homodimers or homo-oligomers seems to be
sufficient to initiate intracellular signaling [27], and TLR4
requires the help of extracellular proteins to function as
receptor for LPS. Clearly, TLR4 is required, but not suffi-
cient for activation of the receptor complex by LPS. The co-
expression of MD-2 is required for optimal TLR4 surface
Fig. 3. The homodimeric TLR4 complexes (the LPS receptor complex). (A) The TLR4/MD-2 complex. TLR4 is co-expressed on the cell surface with MD-2
(which may be soluble, not shown). Bacterial lipopolysaccharide is bound to LBP and then transferred to CD14, which can be found either bound to the plasma
membrane via a glycosylphosphatidylinositol (GPI) anchor or in a soluble form (not shown). All three molecules, TLR4, MD-2, and CD14, participate in LPS
binding. It is assumed that homodimerization must take place to allow signal transduction. One type of TIR domain seems to suffice in the TLR4 homodimer.
(B) The alternative B lymphocyte TLR4 complex. In this LPS complex on B cells, which can be expressed in parallel to the TLR4/MD-2 complex, the Toll-like
protein RP-105 together with MD-1 play the role of MD-2. It is unclear whether CD14 participates in this type of LPS receptor in the same fashion as shown
for TLR4/MD-2. This alternative TLR4 complex activates the src-kinase Lyn and PKCh isoforms in addition to the conventional TLR4 signaling module.
M.U. Martin, H. Wesche / Biochimica et Biophysica Acta 1592 (2002) 265–280 269
expression [82] and function [47,83]. MD-2 is associated
with TLR4 on the extracellular side (sequence alignment
identifies a potential membrane spanning region; however,
MD-2 was also reported to be released in a soluble form
remaining associated with TLR4). Its function is unclear,
although direct binding of LPS was demonstrated [84]. LPS
must be ‘‘presented’’ to TLR4/MD-2 by CD14, either in a
membrane-bound or soluble form. CD14 is well established
as a very potent and high-affinity LPS binding protein
(LBP). Optimal loading of CD14 with LPS is achieved if
the LBP is present (reviewed in Ref. [48]). Thus, the LPS
receptor complex is a multisubunit complex on the extrac-
ellular face of the plasma membrane (Fig. 3A). Cross-
linking studies demonstrated that LPS interacted with all
three components of the TLR4/MD-2/CD14 complex [82].
It was reported that the deletion of the first hundred N-
terminal amino acids in TLR4 containing five leucine-rich
repeats abolished LPS binding, but did not affect MD-2
binding to TLR4 [82]. Signal transduction through the
membrane is achieved by homodimerization. In this case,
one type of TIR domain (that of TLR4) seems sufficient to
initiate the signaling machinery dependent on MyD88 [27]
and Mal/TIRAP [58,59].
In B lymphocytes, a TLR molecule termed RP-105 was
identified which interacts with MD-1 in a fashion similar to
TLR4 with MD-2 [85]. Studies revealed that RP-105/MD-1
may substitute for MD-2 in the TLR-4 complex and thus
form a different LPS receptor complex [86]. Signaling of
this TLR4/RP-105/MD-1 complex may be partially different
to TLR4/MD-2, for example, the activation of the src-family
member Lyn was described under these conditions [87]. It is
presently unclear how the attenuation of TLR4 signaling is
achieved in the complex with RP-105/MD-1 and whether
CD14 is directly involved in such an LPS receptor complex.
RP-105 was also identified in dendritic cells.
3.5. Other TLR receptor complexes
Presently, no information is available on the molecular
composition of the TLR9 receptor complex, which recog-
nizes bacterial CpG-DNA [43,88]. It was reported that this
receptor does not interact with the ligand on the plasma
membrane, but in endosomal compartments. This requires
that the ligands are transported to TLR9 and possibly that
they are modified before optimal binding and signaling can
occur. Whether TLR9 does this all by itself, or if other
molecules participate in the process, is presently unclear. No
information is available on the composition of TLR3, TLR5,
TLR7 or TLR10 receptor complexes.
4. Signaling of the TIR family: the MyD88/IRAK/Tollip
module
The TIR domain is required for signal transduction by all
TIR family members. In the heterodimeric receptor com-
plexes, both individual TIR domains of receptor and core-
ceptor need to be present. Deletion of critical amino acids in
the TIR domain or the whole TIR domain in either type I IL-
1R [89] or IL-1RAcP [90] results in loss of IL-1 responsive-
ness. This has been shown for TLRs as well [80,91].
We will discuss the molecular events leading to signal
generation at the active IL-1R complex as prototype for the
whole TIR family. Although a series of questions remains
open, we suggest a working model that accommodates the
published features of MyD88, IRAK, and Tollip.
4.1. The first step: recruiting IRAK-1 to the receptor
complex by protein–protein interactions
After ligand binding and formation of the heterodimeric
receptor complex, presumably the close spatial association
of the two TIR domains allows homotypic protein–protein
interactions of the TIR domains. As a consequence, the
conformation of the TIR domains is altered, or the combi-
nation of the cytoplasmic domains creates novel scaffolds.
This is allowing an interaction of the adapter proteins
MyD88 and Tollip with the TIR domains at conserved
surface patches, as suggested from the crystal structure of
TIR domains [91].
In this model, MyD88 associates with the TIR domains
of receptor and coreceptor [92,93] possibly as a dimer [94]
and thus introduces death domains into the active receptor
complex. IRAK-1, an IL-1R associated serine/threonine-
specific protein kinase activity identified in 1994 [95] and
cloned in 1995 [96], rapidly translocates to the active
receptor complex and interacts with its N-terminal death
domain with MyD88 [92–94]. Tollip, which is found
associated with IRAK-1 in unstimulated cells, is most likely
interacting with the N-terminal, death domain containing
portion of IRAK-1 (Ref. [97, Kollewe and Martin, unpub-
lished data). In the resting state, Tollip may serve as an
IRAK-1 silencer, possibly by inhibiting IRAK-1 dimeriza-
tion. Upon IL-1 stimulation, the Tollip/IRAK-1 complex is
translocating to the active IL-1R complex. This brings the
death domains of IRAK-1 and MyD88 into close contact.
The two death domains interact most likely in a fashion
similar to the Drosophila homologues Tube and Pelle [98].
Presumably, this results in the dislocation of Tollip, thus
releasing IRAK-1, which is anchored at the active receptor
complex via the death domain protein–protein interaction
with MyD88. We assume that at this stage, dimerization of
IRAK-1 molecules occurs, as dimers can be found in over-
expression systems that are stabilized via phosphorylation-
insensitive homotypic death domain interactions (Kollewe
and Martin, unpublished data).
4.2. The second step: IRAK-1 autophosphorylation and
departure from the receptor complex
Very rapidly, IRAK-1 auto- and/or cross-phosphorylates
itself at the active receptor complex, resulting in phosphor-
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ylation in the kinase domain. In vivo, the very recently
identified IRAK-4 is most likely the kinase that initially
phosphorylates IRAK-1 in the activation loop (see Ref. [8],
Note Added After the Reviewing Process). Subsequently,
IRAK-1 catalyzes multiple (auto)phosphorylations in its
ProST region, a domain between death and kinase domain
which is rich in proline, serine and threonine residues. The
introduction of several negative charges might be the cause
for the release of hyperphosphorylated IRAK-1 from the
receptor complex into the cytoplasm. At this stage, IRAK-1
likely interacts with TAB2 (see below).
4.3. The third step: formation of the IRAK/TRAF6 signal-
osome
In the cytoplasm, IRAK-1 interacts with the downstream
adapter TRAF6. The details of the molecular interaction of
TRAF6 with IRAK-1 are unresolved. However, it was
shown that a truncated form containing the TRAF-N and
TRAF-C domains responsible for homo- and hetero-oligo-
merization of TRAF family members (and for interaction
with other receptor complexes, e.g., CD40) is sufficient to
interact with IRAK-1, although it cannot transduce the
signal further, resulting in a dominant negative effect on
IL-1 stimulated NF-nB activation [99]. In parallel, IRAK-1
also interacts transiently with membrane-associated TAB2,
an adapter protein for the MAPKKK TGFh-activated kinase
1 (TAK1) [100–102] in the mammalian mitogen-activated
protein kinase (MAP-K) signaling cascades (reviewed in
Ref. [103]). It was suggested that IRAK-1 has the function
to introduce TAB2 to a complex consisting of TRAF6 with
TAK1 and its activator protein TAB1 [104]. In this multi-
protein complex, TRAF6 presumably allows the formation
of novel type of polyubiquitin chains and has polyubiqui-
tinylated itself in collaboration with the ubiquitin-conjugat-
ing enzyme complex (E2) consisting of Ubc13 and Uev1A.
TRAF6 functions as an E3 ubiquitin ligase in this process
[105].
Recently, it was proposed that IRAK-1 and TAB2 remain
at the membrane and that TRAF6 translocates to the
membrane to become activated [106]. Previously, it had
been shown that hyperphosphorylated IRAK-1 and TRAF6
can be detected in the cytosol [99].
4.4. The fourth step: downstream signaling events
By an unresolved mechanism, polyubiquitinylated
TRAF6 directly facilitates full activation of TAK1, which
activates itself by autophosphorylation in its activation loop
[107] and then in turn phosphorylates InB-kinase h (IKKh)
specifically at S177 and S181 and MKK6 at S207 and T211,
thus activating the NF-nB pathway as well as p38 and,
surprisingly, c-Jun N-terminal kinase (JNK) [108], which is
normally not phosphorylated by MKK6 (reviewed in Ref.
[103]). Deletion of TRAF6 completely abrogates signaling
of the TIR family [109,110], demonstrating that TRAF6 is
an essential key element in signaling of TIR family mem-
bers. As it was shown that oligomerization of TRAF6 is
sufficient to activate subsequent signaling pathways [111],
the task of IRAK-1 may be twofold: First, to serve as a
scaffold for TRAF6 oligomerization, which may be suffi-
cient for TRAF6 auto-polyubiquitinylation. And second, to
translocate the pivotal TAB2 to TAK1, which is then fully
activated by the modified TRAF6 serving as coactivator
(Fig. 4). The central role for TAK1 was also demonstrated
for LPS signaling [112].
An additional pathway via the adapter molecule ECSIT
(evolutionary conserved signaling intermediate in Toll path-
ways) was described to directly interact and activate
MEKK1 resulting also in NFnB and AP-1 activation. Ex-
pression of dominant negative versions of ECSIT inhibited
constitutive signaling of a CD4/TLR4 chimeric receptor
suggesting involvement of ECSIT also in the TLR sub-
family [113].
NFnB-inducing kinase (NIK) was originally proposed as
a kinase linking TRAFs with IKK activation [114], but was
later shown to be completely dispensable for IL-1 and TNF
signaling [115]. The role of NIK is still not completely clear,
but it appears to be involved in lymphotoxin h signaling.
Finally, direct contact of the adapter molecule p62, which
interacts with the atypical protein kinase C~ (PKC~), was
identified in this multiprotein complex (see below).
4.5. The last step: the fate of IRAK-1 and turning the
signalosome off
The fate of hyperphosphorylated IRAK-1 is proteolytic
degradation (Refs. [116,117], reviewed in Ref. [118]). After
hyperphosphorylation, IRAK-1 is rapidly proteolytically
cleaved, and it was reported that this is dependent on its
phosphorylation state [116,117]. It can be speculated that
upon degradation of IRAK-1, the multiprotein signalosome
centering around TRAF6 dissociates, thus limiting the
duration of the IL-1 response. Indeed, several downstream
events like the activation of NFnB or JNK and p38 kinases
are transient after IL-1 stimulation.
The individual steps involved in termination of the
signaling complex still await detailed clarification.
In summary, it seems that IRAK-1 plays a crucial role
in facilitating the multiprotein signaling complex or sig-
nalosome. IRAK-1 is linking the active receptor complex
to the central adapter and coactivator protein TRAF6.
Thus, IRAK-1 is the switch turning the signalosome on
(by allowing TRAF6 oligomerization and by introducing
TAB2).
IRAK-1 may also be the switch turning the signalosome
off by its autoinduced removal via degradation. Interest-
ingly, the enzymatic activity of IRAK-1 as a protein kinase
does not seem to be required for this function, although it
might have a regulatory role. Consistent with this model, no
substrate for IRAK other than itself and possibly Tollip
[119] has been identified (reviewed in Ref. [118]).
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Presently, there is no indication whatsoever that the
mechanisms discussed here for the IL-1R complex are
different for the IL-18 receptor complex. As far as inves-
tigated, no qualitative differences in the major signal path-
ways activated by IL-18 were revealed to those reported for
IL-1 [73].
5. Are there differences to these initial signaling events
in TLR signaling?
Pathogen-associated structures are very diverse and they
cause a multitude of biological responses in animals or cell
cultures. In the past decades, effects for LPS were reported
which cannot be achieved with IL-1, suggesting that differ-
ences in the signaling mechanisms of TLRs and the IL-1R
exist. These may be due to differential receptor expressions
on different cell types in cell mixtures. In clearly defined
cell lines, no systematic study has been published in which a
consequent comparison of IL-1 and LPS stimulated signal-
ing events or induced genes was investigated. Such a global
comparison will ultimately allow to answer the question
whether the two subfamilies actually use identical pathways
and in fact induce identical gene expression profiles in the
same cellular context.
5.1. The MyD88 knock out phenotype
However, some differences were already found by
comparing IL-1 and LPS effects in MyD88 knock out mice
which suggest that there are MyD88-dependent pathways
and MyD88-independent pathways. Knocking out MyD88
results in the loss of IL-1 and IL-18 signal transduction as
far as tested [63]. Signaling of TLRs is also severely
affected in animals or cell lines lacking MyD88 [64] or
in cells in which dominant-negative versions of MyD88
Fig. 4. The formation of the MyD88/IRAK/TRAF6 signalosome in IL-1 signal transduction. The IL-1-mediated formation of the heterodimeric signaling
receptor complex creates the scaffold for the association of MyD88 and Tollip, thus recruiting IRAK-1 to the active receptor complex. In parallel, IRAK-4 is
recruited to the receptor complex and may phosphorylate IRAK-1 (not shown here), thus initiating further autophosphorylation of IRAK-1.
Hyperphosphorylated IRAK-1 dissociates from the receptor complex and presumably dimerizes. The adapter protein TAB2 is transported by IRAK-1 from
the membrane to the forming signalosome. IRAK-1, presumably as dimer or oligomer, allows dimerization of TRAF6. This activates TRAF6, which becomes
ubiquitinylated. In this active form, TAK1 meets TAB2 and is fully activated by polyubiquitinylated TRAF6 (Ub-TRAF6). This triggers autophosphorylation
of TAK1, which subsequently phosphorylates regulatory kinases in different downstream signaling pathways.
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were expressed [120]. In MyD88 knock out mice or in
dendritic cells derived thereof, LPS or CpG-DNA stimu-
lated pro-inflammatory cytokine production and the induc-
tion of costimulatory molecules such as CD40 were totally
lost. Nevertheless, LPS or CpG-DNA caused caspase-
dependent IL-18 release from pro-IL-18 and some features
of dendritic cell maturation (Refs. [121,122], reviewed in
Ref. [123]). These data suggest that at least some TLRs can
signal via yet unknown pathways in the absence of MyD88
as shown for TLR4 activating PKR [59]. It was shown that
the MyD88-like adapter protein Mal/TIRAP can supple-
ment MyD88 in TLR4 signaling thus explaining some of
the effects observed in the MyD88 knock out situation
[58,59].
5.2. The IRAK-1 knock out phenotype
IRAK-1 knock out animals or cells were investigated
with respect to IL-1 [124,125], IL-18 [126] and LPS
responses [125,127]. Although signaling upon stimulation
with these ligands was reduced, the mice or cells derived
from these were not completely defective in IL-1 response.
It was suggested that this residual signaling was due to
IRAK-2 and/or IRAK-M, two other molecules of the small
IRAK family, which can substitute for IRAK-1 in over-
expression experiments (Refs. [92,128,129], reviewed in
Ref. [118]). The biological function of these kinase-inactive
family members is presently unclear. It was proposed that
kinase-inactive forms may prolong IL-1 signaling because
their half life may be altered similar to that of an IRAK-1
splice variant lacking enzymatic activity [117].
5.3. Further possible differences
There are reports demonstrating that activation of TLR2
induces apoptosis [130,131], an effect normally not achiev-
able by stimulation of IL-1, although some cell lines like
A375 exist in which IL-1 is antiproliferative [132].
Finally, differences may exist in the composition of the
intracellular signaling complex, or signalosome. The iden-
tification of Mal/TIRAP as an additional adapter protein to
MyD88 in TLR4 mediated signaling and the fact that it
interacts preferably with IRAK-2 may explain some of the
differences observed in MyD88 knock outs [58,59]. Finally,
Tollip was reported to be associated with IL-1R or IL-18R
complexes [97], and TLR2 or TLR4, where it was pro-
posed to play an inhibitory role [79,119]; however, its role
in other TLR complexes needs to be further investigated.
Unfortunately, to date, no further information to this
molecule is available and a knock out mouse has not been
reported yet.
The first systematic comparisons of differential activities
mediated by TLR2 and TLR4 in human dendritic cells
revealed differences in cytokine and chemokine transcrip-
tion, although both receptors led to a comparable activation
of MAP-K family members and NFnB [133].
6. Signaling events not directly linked to the MyD88/
IRAK/Tollip module
Three central downstream signaling pathways are de-
pendent on the MyD88/IRAK/Tollip module and on
TRAF6. As discussed above, these are the activation of
the IKK complex resulting in the phosphorylation and
degradation of InB and thus the translocation of NFnB to
the nucleus, the activation of the JNK pathway resulting in
the phosphorylation of AP-1 complexes, and the activation
of the p38 pathway, which is also involved in regulating
mRNA stability [134].
However, IL-1 and LPS stimulate several other signaling
pathways, and the coupling of these to the receptor com-
plexes are not fully understood. It is conceivable that IRAK
functions in two different ways in the IL-1R complex. One
is the adapter function which is responsible for interaction
with TRAF6 (as discussed above). The second function is a
speculative one and is independent of IRAK’s signaling
properties. By its presence, IRAK-1 may stabilize the
active receptor complex due to the strong protein–protein
interactions with MyD88 and possibly Tollip. In such a
situation, signaling pathways not requiring IRAK-1’s
adapter function to TRAF6 could still be dependent on
IRAK-1’s presence. Thus, they would appear as dependent
on IRAK-1 in the IRAK-1- or MyD88-knock out model
systems.
6.1. Involvement of phosphatidylinositol-3 kinase (PI-3-K)
in TIR family signaling
Another pathway reported to be involved in IL-1 signal-
ing is the activation of PI-3-K and subsequently of
protein kinase B (PKB or Akt kinase) [135–139]. It is
unclear whether PI-3-K activation is dependent on IRAK
or not, as unfortunately, neither PI-3-K activation directly
nor PKB activation was investigated in the MyD88 / ,
IRAK 1 / or TRAF6 / situation. On one hand, it
was suggested that PI-3-K was interacting with IRAK [135];
others suggested that direct interaction with the IL-1R was
independent of IRAK [138].
PI-3-K consists of a p110 catalytic subunit and a p85
regulatory subunit. After ligand stimulation, the SH2
domain of p85 interacts with a tyrosine-phosphorylated
motif in receptors. For the type I IL-1R, tyrosine 476 was
identified as potential phosphorylation site and mutation of
this tyrosine resulted in lack of PI-3-K activation [138].
Recently, transient tyrosine phosphorylation of TLR2 at
residues 616 and 761 was demonstrated to be critical for
interaction of p85 with TLR2 [140].
An additional molecule, the low molecular weight G
protein Rac1 of the Rho family was identified as participat-
ing in this pathway [140], which was also reported to be
involved in IL-1-stimulated p65 NFnB transactivation
[141]. Rac1 activation was independent of MyD88 but
relying on IRAK-1 and TRAF6 [142]. Rac1 was found to
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be dependent on the transient phosphorylation of the same
tyrosine in TLR2 required for PI-3-K activation, and it was
speculated that Rac1 is involved in the regulation of PI-3-K
[140]. Rac1 was also reported to be involved in the rapid
formation of focal adhesion points necessary for the activa-
tion of MAP-Ks [143]. This pathway may contribute to the
IKK-independent control of NFnB activity by direct phos-
phorylation events (reviewed in Ref. [144]). In that respect,
it is interesting to note that nuclear translocation of PI-3-K
was also reported upon IL-1 stimulation [139].
6.2. Involvement of other GTP-binding proteins in IL-1
signaling
In the past years, several reports demonstrated that small
GTP binding proteins were involved in IL-1 signal trans-
duction. Ras has been shown to differentially control IL-1-
induced transcription factor activation [145], and IL-1-
induced activation of Raf was discussed to be involved in
transformation of cells [146]. Cdc42 was described to be
involved in activation of the JNK pathway [147,148]. In
most cases, the use of inhibitors or the overexpression of
mutant forms indicated participation of small G proteins
[149,150]. However, some of these claims have been
disputed [151]. A direct association to the IL-1R was
reported for Rho, which is possibly involved in cytoskeletal
reorganization [152]. The association of Rac with PI-3-K in
the receptor complex was discussed above. In summary, the
molecular connection of these proteins to the IL-1R com-
plex remains to be defined.
6.3. Involvement of sphingomyelinases in IL-1 signaling
IL-1 may induce ceramide production by stimulating
neutral and acid sphingomyelinase activities in certain cell
types (reviewed in Ref. [153]). The activation of acid
sphingomyelinase by IL-1 was dependent on the presence
of IL-1RAcP, while that of neutral sphingomyelinase was
not [154]. The consequence of sphingomyelinase activation
for downstream signaling events is controversial [155,156],
and remains unresolved. In addition, the mechanism by
which the two different enzymes couple to the IL-1R
complex is unclear. For the p55 TNF receptor, an adapter
protein (FAN) was described coupling receptor and neutral
sphingomyelinase; however, this protein is not used by the
IL-1R [157].
6.4. Involvement of protein kinase C forms in IL-1 signaling
Ceramide (liberated by sphingomyelinase) is able to
directly activate the atypical protein kinase C~ [158,159].
In addition, PKC~ can be activated in a TRAF6-dependent
manner via the p62 adapter molecule that interacts with the
TRAF domain of TRAF6 [160]. The activation of PKC~
results in the activation of NFnB [161]. PKC~ may also be a
target for Ras-mediated effects as these proteins interact
[162]. The atypical E/L PKC was reported to be involved in
phospholipase A2-catalyzed release of arachidonic acid and
subsequent activation of NFnB [163,164].
A plethora of articles demonstrate the involvement of
PKC isoforms in IL-1 signaling frequently by employing
inhibitors. This IL-1-dependent stimulation of PKC activity
may be due to the release of diacylglycerol after stimulation
of phospholipase activity (Ref. [165], reviewed in Ref.
[153]).
To our knowledge, a direct association of PKC isoforms
to any member of the TIR family has not yet been reported.
6.5. Involvement of phospholipases in IL-1 signaling
IL-1 stimulation of different forms of phospholipases
was reported during the last 10 years [164,166–169]. The
rapid release of arachidonic acid and diacylglycerol affects
downstream effectors such as PKC isoforms. For example, it
was shown that IL-1 can activate PKCa by activating
phosphatidylcholine-specific phospholipase C, resulting in
NFnB-dependent ICAM-1 expression [170], and that IL-1
mediated cyclooxygenase type II and prostaglandin E2
biosynthesis is PKCa-mediated [171].
It is unclear how the formation of the signaling IL-1R
complex is translated into phospholipase activation.
6.6. Involvement of casein kinases in IL-1 signaling
IL-1 stimulates casein kinase II, which was reported to
phosphorylate directly the p65 subunit of NFnB [172]. A
second kinase capable of phosphorylating casein in vitro
was specifically activated by TNF and IL-1 [173]. The
coupling of these kinases and the relative positioning in
the IL-1 and TLR signaling cascade remains unclarified to
date.
7. Concluding remarks
The interest in the TIR family has increased dramatically
in the years since the discovery that TLRs are sensors of the
immune system for pathogen-associated patterns. In the
meantime, we have begun to appreciate that TLRs, in
general, are recognizing danger signals sensing that some-
thing is wrong and needs attention.
An incredible amount of information is rapidly accumu-
lating on TLR ligands, leaving the investigator with the
challenge to find an explanation for a basic question in this
field: How is specificity for the different types of pathogens
achieved?
It seems that groups of pathogen-associated structures
address defined TLRs or combinations of TLRs. Gram-
positive bacteria require a different handling by the immune
system than Gram-negative bacteria, viruses or fungi.
How is this pathogen-specific recognition maintained at
the level of the cellular response, if the signal transduction
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pathways which result in gene induction are identical? The
crucial question is, are they really identical?
First indications point to subtle differences in the com-
position of the initial signalosome between different TIR
family members, which result in an overlapping but distinct
set of signaling pathways finally leading to different
responses of a given cell type. The most prominent example
is the dendritic cell, where different pathogens lead to
skewing of subsequent adaptive immune responses. It
makes sense to maintain specificity, at least in part, during
signal transduction to induce individual gene expression
profiles which take into account that different pathogens
require specific reactions. It is anticipated that the avail-
ability of high-throughput screening systems such as cDNA
arrays will clarify some of the present uncertainties in the
near future. The search for additional signaling pathways
acting in parallel to the ones we discussed here, most
prominently to the MyD88/IRAK/TRAF6-dependent path-
way, may identify pathogen-specific signaling components.
This may give us tools to inhibit undesired effects of
pathogen structures, for example, in sepsis or, alternatively,
stimulate TLR-specific pathways for a better (and more
specific) response, for example, in vaccination protocols.
8. Note added after the reviewing process. Identification
of IRAK-4
Since completing this manuscript, one of us (H.W.) has
published the identification of IRAK-4, a novel member of
the IRAK family [174]. IRAK-4 shows significant
sequence homologies to IRAK-1, IRAK-2 and IRAK-M,
and like IRAK-2 and IRAK-M, it lacks the C-terminal
domain present in IRAK-1. But like IRAK-1, IRAK-4 has
a strong autophosphorylative capacity, that is, kinase
activity, which in contrast to IRAK-1 is indispensable for
IL-1 signaling. The present model is that IRAK-4 is
recruited to the active receptor complex via MyD88 and
death domain interactions, and then initiates signaling by
phosphorylating IRAK-1. This requirement for IRAK-4
can be overcome in in vitro overexpression systems by
autophosphorylation of IRAK-1, resulting in constitutive
activation of downstream signaling pathways. Interestingly,
IRAK-4 cannot substitute for IRAK-1. Knocking out
IRAK-4 completely abolishes signaling for the TIR family,
as reported very recently, pointing to the key role for
IRAK-4 [175].
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